Large holder update, amended
Open the filing on sec.gov
Aptevo Therapeutics Inc. (APVO)
Nasdaq: APVO · Pharmaceutical Preparations · Seattle, WA · filing with the SEC since 2016
The companyfiscal 2022, as filed
Revenue$3.1M-74.7%
Net income$8.0M+128.2%
Earnings per share$920145.60+125.9%
Operating cash flow-$21.0M+3.0%
Cash$22.6M-49.7%
Debt$4.0M-75.0%
Shareholders’ equity$18.0M+1378.1%
Shares, diluted9+12.5%
Return on equity-149.4%
The recordfrom its filings
Filings in 202663
Newest filingNov 12 · SCHEDULE 13G/A
Annual reportMar 26, 2026
Quarterly reportAug 14, 2026
Next report due10-Q by Nov 14
Insider sales, 12 months$0.00
Insider buys, 12 months$0.00
Patents granted13
Filer categoryNon-accelerated filer<br>Smaller reporting company
Trailing twelve months to Jun 2026Net income -$26.4MCash from operations -$25.3Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
As filed, in USD. Nothing here is a forecast.
News
Current report
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Shelf offering
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Employee stock plan registration
Open the filing on sec.gov
Nothing of this kind is on the record for this company yet.
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.